SQ109
SQ109 is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
71.4%
5 of 7 finished
28.6%
2 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design
Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers
Effects of SQ109 on QTc Interval in Healthy Subjects
Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers
Phase IC Study of Safety and PK of SQ109 300mg Daily
Clinical Trials (7)
Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design
Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers
Effects of SQ109 on QTc Interval in Healthy Subjects
Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers
Phase IC Study of Safety and PK of SQ109 300mg Daily
Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB
Dose Escalation Study of SQ109 in Healthy Adult Volunteers
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7